CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 USD | +1.18% |
|
-13.64% | -41.64% |
| Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
| Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 16.93M | Sales 2025 * | 13.83M | Capitalization | 71.04M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M | Net income 2025 * | -69M | EV / Sales 2024 * | 4.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.14 x |
| P/E ratio 2024 * |
-1.33
x | P/E ratio 2025 * |
-1.28
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.18% | ||
| 1 week | -13.64% | ||
| Current month | -24.67% | ||
| 1 month | -24.67% | ||
| 3 months | -27.23% | ||
| 6 months | -44.66% | ||
| Current year | -41.64% |
1 week
1.65
1.98
1 month
1.652.66
Current year
1.653.06
1 year
1.659.77
3 years
1.659.77
5 years
1.659.77
10 years
1.659.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.71 | +1.18% | 174,528 |
| 24-04-17 | 1.69 | -0.59% | 215,000 |
| 24-04-16 | 1.7 | -3.41% | 194,033 |
| 24-04-15 | 1.76 | -8.81% | 190,599 |
| 24-04-12 | 1.93 | -2.53% | 217,650 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.71
USD
Average target price
8.4
USD
Spread / Average Target
+391.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.64% | 71.04M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- CARM Stock
